AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11688250 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin administration
Number of subjects: 0
Study 11688250 — intervention group
Group type: COMPARATOR
Intervention: Control group (no erythropoietin)
Number of subjects: 0
Study 9393422 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics
Number of subjects: 2641
Study 9393422 — intervention group
Group type: COMPARATOR
Intervention: Postoperative antibiotics
Number of subjects: 2641
Study 7895463 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 22
Study 7895463 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 22
Study 3555571 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 0.1 mg kg‐1
Number of subjects: 0
Study 3555571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31558416 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet intervention
Number of subjects: 81
Study 31558416 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 81
Study 31517821 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG‐PS 0/1 and mGPS0
Number of subjects: 40
Study 31517821 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG‐PS 0/1 and NPS0
Number of subjects: 40
Study 31517821 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing ECOG‐PS
Number of subjects: 40
Study 31517821 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing mGPS
Number of subjects: 40
Study 31517821 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing NPS
Number of subjects: 40
Study 27391041 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability-based assessment of anaerobic threshold (HRVT2)
Number of subjects: 11
Study 27391041 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiro-ergometry testing for second ventilatory threshold (VT2)
Number of subjects: 11
Study 27391041 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HRVT2 and VT2
Number of subjects: 11
Study 27391041 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment under normoxic conditions
Number of subjects: 11
Study 26883609 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine
Number of subjects: 102
Study 26883609 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 102
Study 23807984 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynofit (vaginal and perineal dose)
Number of subjects: 120
Study 21144773 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 1200 mg/day for 24 months
Number of subjects: 169
Study 21144773 — intervention group
Group type: COMPARATOR
Intervention: Control group (RAS blockade only)
Number of subjects: 169
Study 19238310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch with capsaicin (CAPS)
Number of subjects: 30
Study 19238310 — intervention group
Group type: COMPARATOR
Intervention: Lunch without capsaicin (Control)
Number of subjects: 30
Study 16723781 — intervention group
Group type: EXPERIMENTAL
Intervention: G643S carriers (n=88)
Number of subjects: 992
Study 16723781 — intervention group
Group type: COMPARATOR
Intervention: Control group (G643G, n=243)
Number of subjects: 992
Study 16089261 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiteness Perfect‐‐10% carbamide peroxide (10% CP)
Number of subjects: 77
Study 16089261 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Platinum‐‐10% carbamide peroxide (10% CP)
Number of subjects: 77
Study 16089261 — intervention group
Group type: EXPERIMENTAL
Intervention: Day White 2Z‐‐7.5% hydrogen peroxide (7.5% HP)
Number of subjects: 77
Study 16089261 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiteness Super‐‐3% CP
Number of subjects: 77
Study 16089261 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence Quick‐‐35% CP
Number of subjects: 77
Study 16089261 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiteness HP‐‐35% HP
Number of subjects: 77
Study 16089261 — intervention group
Group type: COMPARATOR
Intervention: Control (not treated, stored in artificial saliva)
Number of subjects: 77
Study 11305263 — intervention group
Group type: EXPERIMENTAL
Intervention: High-phosphorus diet (3008 mg P and 1995 mg Ca/day for 6 weeks)
Number of subjects: 10
Study 9053501 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 followed by cisplatin 100 mg/m2
Number of subjects: 24
Study 9053501 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 followed by cisplatin 75 mg/m2
Number of subjects: 24
Study 9053501 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2
Number of subjects: 24
Study 7952551 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms twice daily
Number of subjects: 41
Study 7952551 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 1,000 micrograms three times daily
Number of subjects: 41
Study 7952551 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide plus Terbutaline
Number of subjects: 41
Study 7952551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 3311769 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening-detected cancers
Number of subjects: 964
Study 3311769 — intervention group
Group type: COMPARATOR
Intervention: Clinically detected cancers
Number of subjects: 964
Study 3311769 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller tumours detected by screening
Number of subjects: 964
Study 3311769 — intervention group
Group type: COMPARATOR
Intervention: Larger tumours
Number of subjects: 964
Study 29533368 — intervention group
Group type: EXPERIMENTAL
Intervention: YYSG (Chinese herbal medicine capsules)
Number of subjects: 146
Study 29533368 — intervention group
Group type: EXPERIMENTAL
Intervention: YYSG
Number of subjects: 146
Study 29533368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 27871564 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 622
Study 27871564 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 622
Study 24314839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab or bevacizumab treatment (specific drug not detailed)
Number of subjects: 1059
Study 24314839 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic choroidal neovascularization (CNV)
Number of subjects: 1059
Study 24314839 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal retinal thickness >212 μm
Number of subjects: 1059
Study 24314839 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal subretinal tissue complex thickness >275 μm
Number of subjects: 1059
Study 24314839 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal subretinal fluid
Number of subjects: 1059
Study 24314839 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal hyperreflective material (SHRM)
Number of subjects: 1059
Study 24314839 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevation of the retinal pigment epithelium
Number of subjects: 1059
Study 24314839 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrotic scars
Number of subjects: 1059
Study 24314839 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfibrotic scars
Number of subjects: 1059
Study 22771050 — intervention group
Group type: EXPERIMENTAL
Intervention: AXOS 4.8 g/d
Number of subjects: 55
Study 22771050 — intervention group
Group type: EXPERIMENTAL
Intervention: AXOS 2.2 g/d
Number of subjects: 55
Study 22771050 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g/d AXOS)
Number of subjects: 55
Study 19027970 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg/day
Number of subjects: 89
Study 19027970 — intervention group
Group type: COMPARATOR
Intervention: Increased dose of ACE inhibitor
Number of subjects: 89
Study 17655810 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional polypropylene membrane oxygenator
Number of subjects: 20
Study 17655810 — intervention group
Group type: COMPARATOR
Intervention: Plasma-tight poly-(4-methyl-1-pentene) membrane oxygenator
Number of subjects: 20
Study 16243127 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate 20 mg plus metronidazole 0.75% topical lotion
Number of subjects: 40
Study 16243127 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus metronidazole 0.75% topical lotion
Number of subjects: 40
Study 12149101 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation for 1 week
Number of subjects: 68
Study 12149101 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol restriction for 3 weeks
Number of subjects: 68
Study 9800666 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified estrogens + androgen
Number of subjects: 20
Study 9800666 — intervention group
Group type: COMPARATOR
Intervention: Esterified estrogens
Number of subjects: 20
Study 8119599 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorheological manipulation including plasma expansion with hydroxyethyl-starch, withdrawal of whole blood if hematocrit was above 42%, and parenteral pentoxifylline.
Number of subjects: 0
Study 8119599 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 2605993 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (0-2.7% delta 9 THC), 4 cigarettes smoked daily, 2 prior to and 2 during social access period.
Number of subjects: 12
Study 2605993 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (0-2.7% delta 9 THC)
Number of subjects: 12
Study 786676 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of AN 448 t.i.d.
Number of subjects: 30
Study 786676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30518495 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week exercise programme based on aerobic interval and resistance training
Number of subjects: 20
Study 30518495 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) did not participate in any physical activity
Number of subjects: 20
Study 27160187 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Value-Based Purchasing (HVBP) program
Number of subjects: 2430618
Study 27160187 — intervention group
Group type: COMPARATOR
Intervention: Non-HVBP hospitals (control)
Number of subjects: 2430618
Study 27160187 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HVBP vs Non-HVBP hospitals
Number of subjects: 2430618
Study 27160187 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of poor performers at baseline
Number of subjects: 2430618
Study 24884731 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol at 0.7 g/kg
Number of subjects: 220
Study 24884731 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol at 1.0 g/kg
Number of subjects: 220
Study 24884731 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol at 1.4 g/kg
Number of subjects: 220
Study 24884731 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mannitol)
Number of subjects: 220
Study 22293541 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 mg or 75 mg roxatidine capsules given orally to pediatric patients
Number of subjects: 0
Study 22293541 — intervention group
Group type: COMPARATOR
Intervention: 37.5 mg, 75 mg or 150 mg roxatidine capsules given to healthy adult volunteers
Number of subjects: 0
Study 22293541 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose study of roxatidine in pediatric patients
Number of subjects: 0
Study 20386783 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted sockets
Number of subjects: 16
Study 20386783 — intervention group
Group type: COMPARATOR
Intervention: Untreated sockets (Control)
Number of subjects: 16
Study 17198763 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative ultrasound imaging (RUSI) during hypertonic saline condition
Number of subjects: 6
Study 17198763 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitative ultrasound imaging (RUSI) during control condition
Number of subjects: 6
Study 15974219 — intervention group
Group type: EXPERIMENTAL
Intervention: KNO3 plus fluoride dentifrice (Sensodyne Fresh Mint)
Number of subjects: 202
Study 15974219 — intervention group
Group type: COMPARATOR
Intervention: Standard fluoride dentifrice (Crest Regular)
Number of subjects: 202
Study 12839657 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium and calcium supplementation in table salt (10 mmol each daily for 24 months)
Number of subjects: 220
Study 12839657 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 220
Study 11089594 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate solution
Number of subjects: 323
Study 11089594 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol with bisacodyl
Number of subjects: 323
Study 9369819 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction with intravenous oxytocin
Number of subjects: 5041
Study 9369819 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction with vaginal prostaglandin E2 gel
Number of subjects: 5041
Study 9369819 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management with induction if needed
Number of subjects: 5041
Study 1555145 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheter (removed 48 hours post-surgery)
Number of subjects: 67
Study 1555145 — intervention group
Group type: COMPARATOR
Intervention: Intermittent catheterization (every 6 to 8 hours)
Number of subjects: 67
Study 1555145 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheter
Number of subjects: 67
Study 1555145 — intervention group
Group type: COMPARATOR
Intervention: Intermittent catheterization
Number of subjects: 67
Study 3925430 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonacetylated group C polysaccharide C(OAc‐)
Number of subjects: 118
Study 3925430 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylated group C polysaccharide C(OAc+)
Number of subjects: 118
Study 3925430 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (C(OAc‐) and C(OAc+))
Number of subjects: 118
Study 3925430 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 118
Study 30727931 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Antiviral Agents (DAAs), sofosbuvir-based therapies for 12 weeks
Number of subjects: 1716
Study 28930864 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg·d)
Number of subjects: 17
Study 28930864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 26704571 — intervention group
Group type: EXPERIMENTAL
Intervention: PASS (parent-mediated intervention)
Number of subjects: 65
Study 26704571 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 65
Study 24112634 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond lenticule extraction (FLEx)
Number of subjects: 26
Study 24112634 — intervention group
Group type: COMPARATOR
Intervention: Small-incision lenticule extraction (SMILE)
Number of subjects: 26
Study 22041022 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 ppm F
Number of subjects: 80
Study 22041022 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 ppm F plus fTCP
Number of subjects: 80
Study 22041022 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 ppm F
Number of subjects: 80
Study 22041022 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-free (0 ppm F)
Number of subjects: 80
Study 21804894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubigrip
Number of subjects: 79
Study 21804894 — intervention group
Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 79
Study 21804894 — intervention group
Group type: COMPARATOR
Intervention: Futuro splints
Number of subjects: 79
Study 21804894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 79
Study 21804894 — intervention group
Group type: COMPARATOR
Intervention: X‐rays
Number of subjects: 79
Study 17652295 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-sided hip protector on the left or right hip
Number of subjects: 1042
Study 17652295 — intervention group
Group type: COMPARATOR
Intervention: Unprotected hips
Number of subjects: 1042
Study 17652295 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-sided hip protector on the left or right hip (for residents with >80% adherence)
Number of subjects: 1042
Study 17652295 — intervention group
Group type: COMPARATOR
Intervention: Unprotected hips (for residents with >80% adherence)
Number of subjects: 1042
Study 16247129 — intervention group
Group type: EXPERIMENTAL
Intervention: Left posterior oblique (LPO) position during CT gastrography
Number of subjects: 0
Study 16247129 — intervention group
Group type: COMPARATOR
Intervention: Standard supine position during CT gastrography
Number of subjects: 0
Study 11159230 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg every 6 h
Number of subjects: 120
Study 11159230 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol 1 g every 6 h
Number of subjects: 120
Study 11159230 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g every 6 h
Number of subjects: 120
Study 9072602 — intervention group
Group type: EXPERIMENTAL
Intervention: 280 mg estramustine phosphate 2 times daily
Number of subjects: 131
Study 9072602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 8174837 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (evoked by a modified filmed version of Stroop's CWT for 20 min)
Number of subjects: 10
Study 8174837 — intervention group
Group type: COMPARATOR
Intervention: Control (resting quietly for 20 min)
Number of subjects: 10
Study 8174837 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 10
Study 2906888 — intervention group
Group type: COMPARATOR
Intervention: SASP (1 g, n = 21)
Number of subjects: 43
Study 2906888 — intervention group
Group type: EXPERIMENTAL
Intervention: SAB (0.72 g, n = 22)
Number of subjects: 43
Study 2044398 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg naftidrofuryl twice daily in slow-release form
Number of subjects: 78
Study 2044398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 947143 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-lactose skim milk
Number of subjects: 12
Study 947143 — intervention group
Group type: COMPARATOR
Intervention: Skim milk
Number of subjects: 12
Study 947143 — intervention group
Group type: COMPARATOR
Intervention: Lactose (12.5 gm)
Number of subjects: 12
Study 947143 — intervention group
Group type: COMPARATOR
Intervention: Glucose plus galactose (6 gm each)
Number of subjects: 12
Study 31165457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (4 mg·kg−1)
Number of subjects: 130
Study 31165457 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (40 µg)
Number of subjects: 130
Study 27771984 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane inhalation anesthesia (Group I)
Number of subjects: 100
Study 27771984 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anesthesia with ischemic preconditioning (Group TIP)
Number of subjects: 100
Study 27771984 — intervention group
Group type: COMPARATOR
Intervention: Propofol total intravenous anesthesia (Group T)
Number of subjects: 100
Study 26009577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) plus standard therapy of intravenous methylprednisolone (IVMP)
Number of subjects: 170
Study 26009577 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy of intravenous methylprednisolone (IVMP)
Number of subjects: 170
Study 23997695 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure treatment for ≥ 2 months
Number of subjects: 20
Study 21710417 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified case-based reasoning seminars
Number of subjects: 29
Study 21710417 — intervention group
Group type: COMPARATOR
Intervention: Standard case-based reasoning seminars (control)
Number of subjects: 29
Study 19538239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquitous Chronic Disease Care (UCDC) system using cellular phones and the internet
Number of subjects: 123
Study 19538239 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 16620355 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin lispro (0.075 U/kg/hour after a bolus of 0.15 U/kg IV regular insulin)
Number of subjects: 20
Study 16620355 — intervention group
Group type: COMPARATOR
Intervention: Intravenous regular insulin (bolus of 0.15 U/kg followed by infusion)
Number of subjects: 20
Study 15282386 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 18
Study 15282386 — intervention group
Group type: COMPARATOR
Intervention: Air (Control)
Number of subjects: 18
Study 11289469 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c measurement
Number of subjects: 244
Study 11289469 — intervention group
Group type: COMPARATOR
Intervention: FPG measurement
Number of subjects: 244
Study 9226738 — intervention group
Group type: COMPARATOR
Intervention: 20 micrograms/kg nicotine by nasal spray
Number of subjects: 21
Study 9226738 — intervention group
Group type: COMPARATOR
Intervention: 20 micrograms/kg nicotine
Number of subjects: 21
Study 9226738 — intervention group
Group type: COMPARATOR
Intervention: 12 micrograms/kg nicotine
Number of subjects: 21
Study 9226738 — intervention group
Group type: COMPARATOR
Intervention: Subjective measure of 'head rush'
Number of subjects: 21
Study 9226738 — intervention group
Group type: COMPARATOR
Intervention: Self-administration of nicotine
Number of subjects: 21
Study 9226738 — intervention group
Group type: COMPARATOR
Intervention: Self-administration behavior
Number of subjects: 21
Study 9226738 — intervention group
Group type: COMPARATOR
Intervention: Generalization doses
Number of subjects: 21
Study 9226738 — intervention group
Group type: COMPARATOR
Intervention: Confidence in discriminating training doses
Number of subjects: 21
Study 7944440 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous arterial infusion group
Number of subjects: 51
Study 7944440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-dose arterial infusion group
Number of subjects: 51
Study 7944440 — intervention group
Group type: COMPARATOR
Intervention: Repeated one-shot arterial infusion group
Number of subjects: 51
Study 7944440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-dose arterial infusion of 5-FU
Number of subjects: 51
Study 3146989 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 56